October 1, 2026 · Phase 2 readout
BAYRY Phase 2 readout: a negative outcome, -5.4%
-5.4%BAYER (BAYRY) →
On October 1, 2026, Larotrectinib monotherapy — BAYER (Differentiated Thyroid Cancer) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.4% in the window around the event.
The move
$13.50
1d before
$12.77
Event day
$12.77
1d after
$12.77
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+3.4% expected); the stock actually moved -5.4%. Model confidence at the time: 82%.
See the full scored track recordPre-catalyst setup
+2.4%
30-day run-up
2590%
30-day volatility
0.2×
volume spike